Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 1
2001 2
2003 2
2005 2
2006 2
2007 2
2010 1
2011 2
2012 1
2013 4
2014 5
2015 4
2016 9
2017 12
2018 10
2019 13
2020 17
2021 20
2022 11
Text availability
Article attribute
Article type
Publication date

Search Results

103 results
Results by year
Filters applied: . Clear all
Page 1
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. King TE Jr, et al. Among authors: glaspole i. N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836312 Free article. Clinical Trial.
Biomarker signatures for progressive idiopathic pulmonary fibrosis.
Clynick B, Corte TJ, Jo HE, Stewart I, Glaspole IN, Grainge C, Maher TM, Navaratnam V, Hubbard R, Hopkins PMA, Reynolds PN, Chapman S, Zappala C, Keir GJ, Cooper WA, Mahar AM, Ellis S, Goh NS, De Jong E, Cha L, Tan DBA, Leigh L, Oldmeadow C, Walters EH, Jenkins RG, Moodley Y. Clynick B, et al. Among authors: glaspole in. Eur Respir J. 2022 Mar 31;59(3):2101181. doi: 10.1183/13993003.01181-2021. Print 2022 Mar. Eur Respir J. 2022. PMID: 34675050
Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.
Jee AS, Sheehy R, Hopkins P, Corte TJ, Grainge C, Troy LK, Symons K, Spencer LM, Reynolds PN, Chapman S, de Boer S, Reddy T, Holland AE, Chambers DC, Glaspole IN, Jo HE, Bleasel JF, Wrobel JP, Dowman L, Parker MJS, Wilsher ML, Goh NSL, Moodley Y, Keir GJ. Jee AS, et al. Among authors: glaspole in. Respirology. 2021 Jan;26(1):23-51. doi: 10.1111/resp.13977. Epub 2020 Nov 24. Respirology. 2021. PMID: 33233015 Free PMC article.
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser S, Kreuter M. Crestani B, et al. Among authors: glaspole i. Lancet Respir Med. 2019 Jan;7(1):60-68. doi: 10.1016/S2213-2600(18)30339-4. Epub 2018 Sep 14. Lancet Respir Med. 2019. PMID: 30224318 Clinical Trial.
Moderate resting hypoxaemia in fibrotic interstitial lung disease.
Khor YH, Harrison A, Robinson J, Goh NSL, Glaspole I, McDonald CF. Khor YH, et al. Among authors: glaspole i. Eur Respir J. 2021 Jan 28;57(1):2001563. doi: 10.1183/13993003.01563-2020. Print 2021 Jan. Eur Respir J. 2021. PMID: 32859672 Free article. No abstract available.
Progressive fibrosing hypersensitivity pneumonitis: Why wait?
Barnes H, Glaspole IN. Barnes H, et al. Among authors: glaspole in. Respirology. 2022 Mar;27(3):192-193. doi: 10.1111/resp.14225. Epub 2022 Feb 10. Respirology. 2022. PMID: 35146840 Free article. No abstract available.
103 results